CFRXQ
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q3 | -0.50 | $0 | -$9M |
| 2023 Q2 | -1.94 | $0 | -$8M |
| 2023 Q1 | -0.69 | $0 | -$9M |
| 2022 Q4 | -16.14 | $0 | -$10M |
| 2022 Q3 | -34.71 | $0 | -$10M |
| 2022 Q2 | -36.79 | $0 | -$15M |
| 2022 Q1 | -41.00 | $0 | -$12M |
| 2021 Q4 | -8.83 | $0 | -$9M |